Business Wire

NY-ALVAREZ-&-MARSAL

18.1.2023 07:01:35 CET | Business Wire | Press release

Share
Alvarez & Marsal Announces 2023 Managing Director Promotions

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.

Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”

Asia

Henry Chambers, Hong Kong

Eden Chen, Shanghai

Sally Sun, Hong Kong

Brazil

Pedro Bortolotto, São Paulo

Marcelo Compte, São Paulo

Rodrigo Domingues, São Paulo

Lilian Giorgi, São Paulo

Rodrigo Hong, São Paulo

Henrique Kanashiro, São Paulo

Rafael Mendonca Rodrigues, São Paulo

Fabio Missiato, São Paulo

Corporate Performance Improvement

Tiffany Guthrie, Houston

Mike Hall, San Francisco

John McKinnis, Dallas

Sam Rudkin, Atlanta

Consumer and Retail Group

Kenneth Cochran, Charlotte

Jeffrey Dwyer, Chicago

Lakshman Lakshmanan, Dallas

Chad Lusk, Chicago

Joanna Rangarajan, New York

Global Disputes and Investigations

Lee Betteridge, London

Gary Foster, London

EMEA – Performance Improvement

Private Equity Performance Improvement

Nicola Barbini, London

Chris Gobby, London

Britta Mittler, Frankfurt

Till Prinz, Dusseldorf

Tim Veen, Munich

Gerardo Villalba Bello, Madrid

Ysabel Gaspar Zayco, London

Financial Services Industry

Robert Bradbury, London

Dominic Roope, London

Corporate Transformation

Jatin Arora, Dubai

Mark Bennett, Paris

Daran Hopper, London

Dirk Naujokat, Munich

Steve Trainor, London

Diana Wong, London

EMEA Restructuring

Insolvency

Barry Lynch, Grand Cayman

Helen Skeates, London

Turnaround

David Johnston, London

José Miguel Gómez Rivas, Madrid

Middle East

Bill Ozturk, Dubai

Environmental, Social and Governance (ESG)

Stephanie Weiler, Chicago

Healthcare Industry Group

JoyAnn Book, Phoenix

Bianca A. Briola Charlotte

David Nidetz, Detroit

Rich Rieger, Chicago

India

Anup Gandhi, Mumbai

Pranav Sheth, Mumbai

Infrastructure & Capital Projects

Sue Frost, Washington, D.C.

Alan Richard, Washington, D.C.

Private Equity Performance Group

Kent Edgerton, Nashville

Jana Gold, Washington, D.C.

Brad Howard, New York

Larry Thomas, Tampa

Klaus Weisenberger, San Francisco

Public Sector

Daniel Harlan, Washington, D.C

Restructuring & Turnaround (North America)

Taylor Atwood, Dallas

Matthew Davidson, Detroit

Chad Ellison, Calgary

Kamila Khairoullina, New York

Mark Sidorenkov, Phoenix

Jeff Sielinski, Detroit

Michael Zembillas, Atlanta

Global Taxand

Simon Bernstein, New York

Stephanie Doughty, Houston

Michael Farkas, New York

Simon Gore, London

Jack Hollyman, London

Jac Emilio Martinez, Miami

Joseph Plati, New York

Brendan Sinnott, New York

Katya Umanskaya, Los Angeles

Global Transaction Advisory Group

Anuj Astir, New York

Nout Brugman, Amsterdam

David Cho, Chicago

Vitor Garcia, Sao Paulo

Jimmy Glenn, Atlanta

Nick Lynch, London

Jai Tandan, Mumbai

Rhett Taylor, Nashville

Nick Thoele, New York

Cedric Zana, Paris

Valuation Services

Cole Corbin, New York

Steven Fischoff, Chicago

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.

With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.

To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye